Malaria vaccine: A lifesaving breakthrough struggles for funding, not effectiveness
This article draws attention to a major problem impeding the rollout of malaria vaccines in Africa. It draws attention to a double standard in global health: whereas wealthier countries easily spend money on pricey vaccines, African countries have to consider cost-effectiveness, even when the vaccines have proven to be successful. The article argues that the issue is one of equality rather than just cost or efficiency. It urges world leaders to view malaria vaccinations as a moral duty rather than just a financial one.